✦ LIBER ✦

Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

✍ Scribed by Ghanem, Hady; Kantarjian, Hagop; Cortes, Jorge; Quintás-Cardama, Alfonso; Jabbour, Elias

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Class effects of tyrosine kinase inhibit

✍ Giles, F J; O'Dwyer, M; Swords, R 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 315 KB

Impact of comorbidities on the treatment

✍ Gugliotta, Gabriele; Castagnetti, Fausto; Fogli, Miriam; Cavo, Michele; Baccaran 📂 Article 📅 2013 🏛 Expert Reviews 🌐 English ⚖ 320 KB

Management of adverse events associated

✍ Jabbour, E; Deininger, M; Hochhaus, A 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 423 KB

Management of adverse events associated

✍ Jabbour, E; Deininger, M; Hochhaus, A 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 58 KB

Importance of adherence to BCR-ABL tyros

✍ de Almeida, Maria Helena; Fogliatto, Laura; Couto, Dulce 📂 Article 📅 2014 🏛 SciELO 🌐 English ⚖ 170 KB

Tyrosine Kinase Inhibitors as Initial Th

✍ Ohanian, Maro; Kantarjian, Hagop M.; Quintas-Cardama, Alfonso; Jabbour, Elias; A 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 862 KB